Tech Company Financing Transactions
AnaptysBio Funding Round
AnaptysBio, based in San Diego, secured $40 million from BioMed Ventures, BVF Partners and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
7/16/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series D
Investors
Frazier Healthcare Partners (James Topper)
Novo Ventures (Tiba Aynechi)
Proceeds Purpose
Proceeds from the financing are intended to advance AnaptysBio's first-in-class anti-IL-33 and anti-IL-36 receptor antibody programs through key Phase II studies. The financing will also support the continued discovery of novel therapeutic antibodies against emerging target biology in inflammation and immuno-oncology using AnaptysBio's proprietary somatic hypermutation-based antibody discovery platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
10421 Pacific Center Ct. 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
AnaptysBio (NASDAQ: ANAB) is a leading biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hamza Suria
Chief Financial Officer
Eric Loumeau
Chief Medical Officer
Marco Londei
Vice President
Margaret Marino
Vice President
Jason Pinkstaff
Vice President
Nancy Sacco
VP - Manufacturing
Hemant Kumar
VP - Regulatory Affairs
Lewis Gryziewicz
Browse more venture capital transactions:
Prev: 7/16/2015: Workspot venture capital transaction
Next: 7/16/2015: CircleBack venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs